SequelSEC

Editas Medicine, Inc. EDIT

Biological Products, (No Diagnostic Substances) · CIK 0001650664 · Fiscal year ends 1231

Revenue
$47.00M
Fiscal year ended 2026-06-30
Operating income
-$75.86M
Fiscal year ended 2026-06-30
Free cash flow
-$120.55M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$191.38MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.96Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue4.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity7.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Long-term debt / equity1.96x81th
CapEx / revenue1.5%28th
Revenue YoY growth25.4%63th
SBC / revenue24.7%39th
Current ratio3.54x40th
FCF margin-409.3%40th
Net margin-395.0%46th
Operating margin-394.9%46th
R&D / revenue222.0%48th

Editas Medicine, Inc. (EDIT) reported revenue of $47.00M and net income of -$73.95M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Editas Medicine, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Editas Medicine, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$47.00M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$75.86M
Net income-$73.95M
Research & development$84.96M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$45.51M
Selling & marketingUnavailable

Balance

Editas Medicine, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$181.82M
Total assets$237.36M
Current assets$218.07M
Total liabilities$132.08M
Current liabilities$68.43M
Total equity incl. NCI$105.28M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$2.72M
GoodwillUnavailable
Long-term debt$48.24M
Accounts payable$4.74M

Cash flow

Editas Medicine, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$119.86M
Capital expenditures$691.00K
Investing cash flow$9.90M
Financing cash flow$152.03M
Net change in cash$42.07M
Stock-based compensation$8.65M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Editas Medicine, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$120.55M
Gross marginUnavailable
Operating margin-161.4%
FCF margin-256.5%
SBC / revenue18.4%
Current ratio3.19x
Revenue YoY growth20.8%
Net margin-157.3%
R&D / revenue180.7%
CapEx / revenue1.5%
Long-term debt / equity0.46x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EDIT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.